Eloxx Pharmaceuticals Inc

Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid-modulating drug candidates. The firm focuses on the the formulation of medicines to treat rare and ultra-rare premature stop codon diseases. Its lead product candidate is ELX-02, a small molecule drug designed to restore production of full-length functional proteins. It operates through the United States and Israel geographical segments. The company was founded by Silvia Noiman on December 19, 2017 and is headquartered in Watertown, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Phase 2 cystic fibrosis program for ELX-02 expected to be fully enrolled in the first quarter of 2020 and topline results expected during the first half of 2020

Eloxx Pharmaceuticals Provides Update on Progress of Its Phase 2 Clinical Programs for ELX-02 and ERSG Pipeline at Biotech Showcase™

As of late, it has definitely been a great time to be an investor in Eloxx.

Will Eloxx Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Eloxx Pharmaceuticals, Inc. (ELOX).

Eloxx Pharmaceuticals, Inc. (ELOX) Shares March Higher, Can It Continue?

Eloxx Preliminary CF Data Should Be Monitored Closely As It Advances Forward

Eloxx Pharmaceuticals, Inc. (ELOX) CEO Robert Ward on Q3 2019 Results - Earnings Call Transcript

Results of our renal impairment study for ELX-02 support the expansion of our research in the kidney beyond nephropathic cystinosis into other areas such as autosomal dominant polycystic kidney disease Results of our renal impairment study for ELX-02 support the expansion of our research in the kidney beyond nephropathic cystinosis into other areas such as autosomal dominant polycystic kidney disease

Eloxx Pharmaceuticals Presents New Positive Data for ELX-02 at the American Society of Nephrology (ASN) Kidney Week 2019

CF Foundation and Eloxx to form joint program advisory group focused on the development of ELX-02 for cystic fibrosis

Eloxx Pharmaceuticals Announces Cystic Fibrosis Foundation (CF Foundation) To Provide Funding and Support for ELX-02 U.S. Phase 2 Clinical Trial

WALTHAM, Mass., Sept.  16, 2019  (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that Robert E. Ward, Chairman and Chief Executive Officer of Eloxx, will make a presentation and host one-on-one meetings with investors at the 2019 Cantor Global Healthcare Conference on October 3rd, 2019 at the InterContinental New York Barclay Hotel.

Eloxx Pharmaceuticals to Present at the 2019 Cantor Global Healthcare  Conference on October 3rd, 2019

WALTHAM, Mass., Sept.  10, 2019  (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that Robert E. Ward, Chairman and Chief Executive Officer of Eloxx, will host one-on-one meetings with investors at the Oppenheimer Fall Summit focused on Specialty Pharma & Rare Diseases on September 24, 2019 at the Parker New York Hotel.

Eloxx Pharmaceuticals to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Diseases on September 24, 2019

WALTHAM, Mass., Aug.  26, 2019  (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that Robert E. Ward, Chairman and Chief Executive Officer of Eloxx, will host one-on-one meetings with investors at the 14 th  Annual Citi Biotech C  onference  on September 5th, 2019 at the Four Seasons Boston, Massachusetts.

Eloxx Pharmaceuticals to Participate in the 14th Annual Citi Biotech Conference on September 5th, 2019

Eloxx Pharmaceuticals, Inc. (ELOX) CEO Robert Ward on Q2 2019 Results - Earnings Call Transcript

Advanced Micro Devices

Ciena

As the market played a waiting game, good news lifted several companies higher.

Why Advanced Micro Devices, Ciena, and Eloxx Pharmaceuticals Jumped Today

Eloxx Pharmaceuticals (NASDAQ: ELOX) shares spiked higher after the company presented data for its lead investigational drug, ELX-02, at the 42nd European Cystic Fibrosis Society Conference.

Eloxx Pharma Says ELX-02 Data Showed Increases In Key Metric

Eloxx Pharmaceuticals' (ELOX) CEO Robert Ward on Q1 2019 Results - Earnings Call Transcript

News for Eloxx Pharmaceuticals Inc Stock (ELOX)